California State Teachers Retirement System Purchases 10,540 Shares of Kymera Therapeutics, Inc. $KYMR

California State Teachers Retirement System increased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 23.0% during the first quarter, Holdings Channel reports. The fund owned 56,282 shares of the company’s stock after purchasing an additional 10,540 shares during the period. California State Teachers Retirement System’s holdings in Kymera Therapeutics were worth $4,688,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. State of New Jersey Common Pension Fund D bought a new stake in Kymera Therapeutics during the 4th quarter worth about $2,610,000. Vanguard Group Inc. raised its position in Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after purchasing an additional 845,922 shares during the last quarter. Maven Securities LTD bought a new position in Kymera Therapeutics in the 4th quarter worth approximately $1,167,000. Eagle Health Investments LP acquired a new position in Kymera Therapeutics during the 4th quarter worth $10,606,000. Finally, Monashee Investment Management LLC acquired a new position in Kymera Therapeutics during the 4th quarter worth $7,781,000.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on KYMR. Deutsche Bank Aktiengesellschaft started coverage on Kymera Therapeutics in a research report on Thursday, July 30th. They set a “hold” rating and a $120.00 target price for the company. Guggenheim raised their target price on shares of Kymera Therapeutics from $125.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, July 28th. Bank of America lifted their target price on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Citigroup reiterated a “buy” rating on shares of Kymera Therapeutics in a research report on Thursday. Finally, Mizuho increased their price target on Kymera Therapeutics from $120.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, July 16th. Twenty investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $125.65.

Insider Buying and Selling

In other news, Director Bruce Booth sold 467,878 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the sale, the director owned 472,267 shares in the company, valued at $52,086,327.43. This represents a 49.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 80,000 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total value of $9,223,200.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at approximately $76,848,624.72. The trade was a 10.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 3,607,813 shares of company stock worth $387,818,004 over the last 90 days. 15.98% of the stock is currently owned by insiders.

Kymera Therapeutics Stock Up 1.0%

NASDAQ KYMR opened at $107.52 on Friday. The firm’s 50 day moving average is $101.31 and its 200-day moving average is $88.79. The company has a market capitalization of $8.94 billion, a PE ratio of -33.19 and a beta of 1.95. Kymera Therapeutics, Inc. has a 12-month low of $36.65 and a 12-month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.82%. The business had revenue of $65.00 million during the quarter, compared to analysts’ expectations of $32.78 million. During the same quarter in the prior year, the company posted ($0.95) earnings per share. The firm’s revenue was up 465.2% on a year-over-year basis. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.44 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.